Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Assets (2020 - 2025)

Cellebrite DI's Assets history spans 6 years, with the latest figure at $938.9 million for Q4 2025.

  • Quarterly Assets rose 35.95% to $938.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $938.9 million through Dec 2025, up 35.95% year-over-year, with the annual reading at $938.9 million for FY2025, 35.95% up from the prior year.
  • Assets came in at $938.9 million for Q4 2025, up from $834.3 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $938.9 million in Q4 2025 to a low of $315.1 million in Q3 2021.
  • The 5-year median for Assets is $503.0 million (2023), against an average of $532.5 million.
  • Year-over-year, Assets fell 6.75% in 2021 and then surged 41.47% in 2025.
  • Cellebrite DI's Assets stood at $339.8 million in 2021, then increased by 18.69% to $403.3 million in 2022, then surged by 32.13% to $532.9 million in 2023, then increased by 29.59% to $690.6 million in 2024, then soared by 35.95% to $938.9 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Assets are $938.9 million (Q4 2025), $834.3 million (Q3 2025), and $787.4 million (Q2 2025).